2025 annual financial data
Scribe Therapeutics 2025 Operating margin
Scribe Therapeutics 2025 operating margin with verified reported values.
Direct answer
Operating margin was -50.94%.
Operating income was -26,070,000 USD and net income was -21,808,000 USD.
Operating cash flow was -45,213,000 USD.
Get free Scribe Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 51,174,000 USD
- Operating income
- -26,070,000 USD
- Net income
- -21,808,000 USD
- Operating cash flow
- -45,213,000 USD